FOXD1 Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer.
By: Sohei Nakayama, Kenzo Soejima, Hiroyuki Yasuda, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Norihiro Yamaguchi, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Katsuhiko Naoki, Tomoko Betsuyaku
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
2015-1-1; doi:
2015-1-1; doi:
Abstract
Aim
Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).
Materials
Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.
Results
FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.
Conclusion
The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.
Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
PMID:25550559
